


VII

is a chiral carbon and said compound or salt is the (S)-enantiomer.

53. A pharmaceutical composition comprising a compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
54. A method of inhibiting an activity of a PI3K kinase, comprising contacting the kinase with a compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof.
55. The method of claim 54, wherein the PI3K is selected from the group consisting of PI3K α , PI3K β , PI3K γ , and PI3K δ .
56. The method of claim 54, wherein the PI3K comprises a mutation.
57. The method of any one of claims 54 to 56, wherein said compound is a selective inhibitor for PI3K δ over one or more of PI3K α , PI3K β , and PI3K γ .
58. A method of treating a disease in a patient, wherein said disease is associated with abnormal expression or activity of a PI3K kinase, comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof.
59. The method of claim 58, wherein said disease is osteoarthritis, restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, inflammation, angiogenesis, pancreatitis, kidney disease, inflammatory bowel disease, myasthenia gravis, multiple sclerosis, or Sjögren's syndrome.

60. The method of any one of claims 58 to 59, wherein more than one of said compounds is administered.
61. The method of claim 60, wherein the compound is administered in combination with a kinase inhibitor that inhibits a kinase other than a PI3K kinase.
62. A method of treating an immune-based disease in a patient, comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof.
63. The method of claim 62, wherein said immune-based disease is rheumatoid arthritis, allergy, asthma, glomerulonephritis, lupus, or inflammation related to any of the aforementioned.
64. A method of treating a cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof.
65. The method of claim 64, wherein said cancer is breast, prostate, colon, endometrial, brain, bladder, skin, uterus, ovary, lung, pancreatic, renal, gastric, or a hematological cancer.
66. The method of claim 65, wherein said hematological cancer is acute myeloblastic leukemia, chronic myeloid leukemia, or B cell lymphoma.
67. A method of treating a lung disease in a patient, comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof.
68. The method of claim 67, wherein said lung disease is acute lung injury (ALI) or adult respiratory distress syndrome (ARDS).



VII

is a chiral carbon and said compound or salt is the (S)-enantiomer.

53. A pharmaceutical composition comprising a compound of any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.